{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T13:24:04Z","timestamp":1787664244342,"version":"build-2736575974"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s10147-026-03088-x","type":"journal-article","created":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T05:58:39Z","timestamp":1782971919000},"page":"1858-1868","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prediction of chemotherapy-induced nausea during irinotecan-based treatment based on prior oxaliplatin-induced symptoms in colorectal cancer"],"prefix":"10.1007","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-9821-7917","authenticated-orcid":false,"given":"Yoshitaka","family":"Saito","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoh","family":"Takekuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshito","family":"Komatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuru","family":"Sugawara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,1]]},"reference":[{"key":"3088_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10147-019-01485-z","volume":"25","author":"Y Hashiguchi","year":"2020","unstructured":"Hashiguchi Y, Muro K, Saito Y et al (2020) Japanese society for cancer of the colon and rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer. Int J Clin Oncol 25:1\u201342. https:\/\/doi.org\/10.1007\/s10147-019-01485-z","journal-title":"Int J Clin Oncol"},{"key":"3088_CR2","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1200\/JGO.19.00367","volume":"6","author":"EG Chiorean","year":"2020","unstructured":"Chiorean EG, Nandakumar G, Fadelu T et al (2020) Treatment of patients with late-stage colorectal cancer: ASCO resource-stratified guideline. JCO Glob Oncol 6:414\u2013438. https:\/\/doi.org\/10.1200\/JGO.19.00367","journal-title":"JCO Glob Oncol"},{"key":"3088_CR3","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1200\/JCO.22.01690","volume":"41","author":"VK Morris","year":"2023","unstructured":"Morris VK, Kennedy EB, Baxter NN et al (2023) Treatment of metastatic colorectal cancer: ASCO guideline. ASCO Guideline J Clin Oncol 41:678\u2013700. https:\/\/doi.org\/10.1200\/JCO.22.01690","journal-title":"ASCO Guideline J Clin Oncol"},{"key":"3088_CR4","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.annonc.2022.10.003","volume":"34","author":"A Cervantes","year":"2023","unstructured":"Cervantes A, Adam R, Rosell\u00f3 S et al (2023) Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol 34:10\u201332. https:\/\/doi.org\/10.1016\/j.annonc.2022.10.003","journal-title":"Ann Oncol"},{"key":"3088_CR5","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1634\/theoncologist.2-6-402","volume":"2","author":"LB Saltz","year":"1997","unstructured":"Saltz LB (1997) Clinical use of irinotecan: current status and future considerations. Oncologist 2:402\u2013409. https:\/\/doi.org\/10.1634\/theoncologist.2-6-402","journal-title":"Oncologist"},{"key":"3088_CR6","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1200\/JCO.2007.14.9898","volume":"26","author":"J Cassidy","year":"2008","unstructured":"Cassidy J, Clarke S, D\u00edaz-Rubio E et al (2008) Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil\/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J Clin Oncol 26:2006\u20132012. https:\/\/doi.org\/10.1200\/JCO.2007.14.9898","journal-title":"J Clin Oncol"},{"key":"3088_CR7","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/s00520-023-08220-5","volume":"32","author":"K Jordan","year":"2023","unstructured":"Jordan K, Chan A, Gralla RJ et al (2023) Emetic risk classification and evaluation of the emetogenicity of antineoplastic agents-updated MASCC\/ESMO consensus recommendation. Support Care Cancer 32:53. https:\/\/doi.org\/10.1007\/s00520-023-08220-5","journal-title":"Support Care Cancer"},{"key":"3088_CR8","doi-asserted-by":"publisher","first-page":"2782","DOI":"10.1200\/JCO.20.01296","volume":"38","author":"PJ Hesketh","year":"2020","unstructured":"Hesketh PJ, Kris MG, Basch E et al (2020) Antiemetics: ASCO guideline update. J Clin Oncol 38:2782\u20132797. https:\/\/doi.org\/10.1200\/JCO.20.01296","journal-title":"J Clin Oncol"},{"key":"3088_CR9","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1007\/s10147-024-02535-x","volume":"29","author":"H Iihara","year":"2024","unstructured":"Iihara H, Abe M, Wada M et al (2024) 2023 Japan Society of clinical oncology clinical practice guidelines update for antiemesis. Int J Clin Oncol 29:873\u2013888. https:\/\/doi.org\/10.1007\/s10147-024-02535-x","journal-title":"Int J Clin Oncol"},{"key":"3088_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10147-020-01818-3","volume":"26","author":"K Aogi","year":"2021","unstructured":"Aogi K, Takeuchi H, Saeki T et al (2021) Optimizing antiemetic treatment for chemotherapy-induced nausea and vomiting in Japan: update summary of the 2015 Japan Society of Clinical Oncology Clinical Practice Guidelines for antiemesis. Int J Clin Oncol 26:1\u201317. https:\/\/doi.org\/10.1007\/s10147-020-01818-3","journal-title":"Int J Clin Oncol"},{"key":"3088_CR11","unstructured":"(2025) NCCN clinical practice guidelines in oncology, antiemesis, version 2. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/antiemesis.pdf"},{"key":"3088_CR12","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/s40265-013-0019-1","volume":"73","author":"RM Navari","year":"2013","unstructured":"Navari RM (2013) Management of chemotherapy-induced nausea and vomiting\u202f: focus on newer agents and new uses for older agents. Drugs 73:249\u2013262. https:\/\/doi.org\/10.1007\/s40265-013-0019-1","journal-title":"Drugs"},{"key":"3088_CR13","doi-asserted-by":"publisher","first-page":"4249","DOI":"10.2147\/CMAR.S176574","volume":"10","author":"T Hayashi","year":"2018","unstructured":"Hayashi T, Shimokawa M, Matsuo K et al (2018) Risk factors for delayed chemotherapy-induced nausea and vomiting with low-emetic-risk chemotherapy: a prospective, observational, multicenter study. Cancer Manag Res 10:4249\u20134255. https:\/\/doi.org\/10.2147\/CMAR.S176574","journal-title":"Cancer Manag Res"},{"key":"3088_CR14","doi-asserted-by":"publisher","unstructured":"Saito Y, Watanabe T, Takekuma Y et al (2026) Evaluating the potential to predict chemotherapy-induced nausea and vomiting in carboplatin-containing treatment based on symptoms induced by prior cisplatin-containing treatment. Sci Rep https:\/\/doi.org\/10.1038\/s41598-026-36488-0, Epub ahead of print","DOI":"10.1038\/s41598-026-36488-0"},{"key":"3088_CR15","doi-asserted-by":"publisher","first-page":"e2250030","DOI":"10.1001\/jamanetworkopen.2022.50030","volume":"6","author":"SM Koroukian","year":"2023","unstructured":"Koroukian SM, Booker BD, Vu L et al (2023) Receipt of targeted therapy and survival outcomes in patients with metastatic colorectal cancer. JAMA Netw Open 6:e2250030. https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.50030","journal-title":"JAMA Netw Open"},{"key":"3088_CR16","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1093\/jjco\/hyae110","volume":"54","author":"A Takashima","year":"2024","unstructured":"Takashima A, Ishiguro M, Sasaki K et al (2024) Real-world treatment costs of first-line treatment for metastatic colorectal cancer: a survey of the JCOG colorectal cancer study group. Jpn J Clin Oncol 54:1107\u20131114. https:\/\/doi.org\/10.1093\/jjco\/hyae110","journal-title":"Jpn J Clin Oncol"},{"key":"3088_CR17","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1093\/annonc\/mdx816","volume":"29","author":"Y Yamada","year":"2018","unstructured":"Yamada Y, Denda T, Gamoh M et al (2018) S-1 and irinotecan plus bevacizumab versus mFOLFOX6 or CapeOX plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer (TRICOLORE): a randomized, open-label, phase III, noninferiority trial. Ann Oncol 29:624\u2013631. https:\/\/doi.org\/10.1093\/annonc\/mdx816","journal-title":"Ann Oncol"},{"key":"3088_CR18","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1001\/jama.2023.4428","volume":"329","author":"J Watanabe","year":"2023","unstructured":"Watanabe J, Muro K, Shitara K et al (2023) Panitumumab vs bevacizumab added to standard first-line chemotherapy and overall survival among patients with RAS wild-type, left-sided metastatic colorectal cancer: A randomized clinical trial. JAMA 329:1271\u20131282. https:\/\/doi.org\/10.1001\/jama.2023.4428","journal-title":"JAMA"},{"key":"3088_CR19","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1016\/S1470-2045(14)70330-4","volume":"15","author":"V Heinemann","year":"2014","unstructured":"Heinemann V, von Weikersthal LF, Decker T et al (2014) FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol 15:1065\u20131075. https:\/\/doi.org\/10.1016\/S1470-2045(14)70330-4","journal-title":"Lancet Oncol"},{"key":"3088_CR20","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/S1470-2045(15)70127-0","volume":"16","author":"J Tabernero","year":"2015","unstructured":"Tabernero J, Yoshino T, Cohn AL et al (2015) Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study. Lancet Oncol 16:499\u2013508. https:\/\/doi.org\/10.1016\/S1470-2045(15)70127-0","journal-title":"Lancet Oncol"},{"key":"3088_CR21","doi-asserted-by":"publisher","first-page":"3499","DOI":"10.1200\/JCO.2012.42.8201","volume":"30","author":"E Van Cutsem","year":"2012","unstructured":"Van Cutsem E, Tabernero J, Lakomy R et al (2012) Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol 30:3499\u20133506. https:\/\/doi.org\/10.1200\/JCO.2012.42.8201","journal-title":"J Clin Oncol"},{"key":"3088_CR22","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1016\/S1470-2045(18)30140-2","volume":"19","author":"RH Xu","year":"2018","unstructured":"Xu RH, Muro K, Morita S et al (2018) Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial. Lancet Oncol 19:660\u2013671. https:\/\/doi.org\/10.1016\/S1470-2045(18)30140-2","journal-title":"Lancet Oncol"},{"key":"3088_CR23","doi-asserted-by":"publisher","first-page":"213","DOI":"10.5414\/CP204531","volume":"62","author":"T Watanabe","year":"2024","unstructured":"Watanabe T, Saito Y, Takekuma Y et al (2024) Evaluation of the risk factors for the failure of a single prophylactic dose of anticholinergic drugs for irinotecan-induced cholinergic symptoms. Int J Clin Pharmacol Ther 62:213\u2013221. https:\/\/doi.org\/10.5414\/CP204531","journal-title":"Int J Clin Pharmacol Ther"},{"key":"3088_CR24","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1007\/s00520-011-1286-6","volume":"19","author":"PJ Hesketh","year":"2011","unstructured":"Hesketh PJ, Bosnjak SM, Nikolic V et al (2011) Incidence of delayed nausea and vomiting in patients with colorectal cancer receiving irinotecan-based chemotherapy. Support Care Cancer 19:2063\u20132066. https:\/\/doi.org\/10.1007\/s00520-011-1286-6","journal-title":"Support Care Cancer"},{"key":"3088_CR25","doi-asserted-by":"publisher","first-page":"2323","DOI":"10.1007\/s00384-020-03731-7","volume":"35","author":"S Takei","year":"2020","unstructured":"Takei S, Ishibe A, Watanabe J et al (2020) Risk factors of chemotherapy-induced nausea and vomiting in patients with metastatic colorectal cancer: a prospective cohort study (YCOG1301). Int J Colorectal Dis 35:2323\u20132329. https:\/\/doi.org\/10.1007\/s00384-020-03731-7","journal-title":"Int J Colorectal Dis"},{"key":"3088_CR26","doi-asserted-by":"publisher","first-page":"e173","DOI":"10.1634\/theoncologist.2020-0305","volume":"26","author":"MJDL van der Vorst","year":"2021","unstructured":"van der Vorst MJDL, Toffoli EC, Beusink M et al (2021) Metoclopramide, dexamethasone, or palonosetron for prevention of delayed chemotherapy-induced nausea and vomiting after moderately emetogenic chemotherapy (MEDEA): a randomized, phase III, noninferiority trial. Oncologist 26:e173\u2013e181. https:\/\/doi.org\/10.1634\/theoncologist.2020-0305","journal-title":"Oncologist"},{"key":"3088_CR27","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.annonc.2024.09.001","volume":"36","author":"H Sakai","year":"2025","unstructured":"Sakai H, Tsurutani J, Ozaki Y et al (2025) A randomized, double-blind, placebo-controlled phase II study of olanzapine-based prophylactic antiemetic therapy for delayed and persistent nausea and vomiting in patients with HER2-positive or HER2-low breast cancer treated with trastuzumab deruxtecan: ERICA study (WJOG14320B). Ann Oncol 36:31\u201342. https:\/\/doi.org\/10.1016\/j.annonc.2024.09.001","journal-title":"Ann Oncol"},{"key":"3088_CR28","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1007\/s00520-025-09528-0","volume":"33","author":"N Wewala","year":"2025","unstructured":"Wewala N, Kim Y, Sharples K et al (2025) Proton pump inhibition to prevent delayed chemotherapy-induced nausea and vomiting in patients receiving adjuvant or neoadjuvant breast cancer chemotherapy: a phase II, randomised double-blind crossover trial (PantoCIN). Support Care Cancer 33:484. https:\/\/doi.org\/10.1007\/s00520-025-09528-0","journal-title":"Support Care Cancer"},{"key":"3088_CR29","doi-asserted-by":"publisher","first-page":"569","DOI":"10.7150\/jca.13637","volume":"7","author":"H Iihara","year":"2016","unstructured":"Iihara H, Ishihara M, Fujii H et al (2016) Comparison of the Control of Nausea and Vomiting among Several Moderately Emetic-Risk Chemotherapy Regimens. J Cancer 7:569\u2013575. https:\/\/doi.org\/10.7150\/jca.13637","journal-title":"J Cancer"},{"key":"3088_CR30","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1016\/j.ejca.2015.03.024","volume":"51","author":"J Nishimura","year":"2015","unstructured":"Nishimura J, Satoh T, Fukunaga M et al (2015) Combination antiemetic therapy with aprepitant\/fosaprepitant in patients with colorectal cancer receiving oxaliplatin-based chemotherapy (SENRI trial): a multicentre, randomised, controlled phase 3 trial. Eur J Cancer 51:1274\u20131282. https:\/\/doi.org\/10.1016\/j.ejca.2015.03.024","journal-title":"Eur J Cancer"},{"key":"3088_CR31","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1093\/annonc\/mdv482","volume":"27","author":"C Weinstein","year":"2016","unstructured":"Weinstein C, Jordan K, Green SA et al (2016) Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy: results of a randomized, double-blind phase III trial. Ann Oncol 27:172\u2013178. https:\/\/doi.org\/10.1093\/annonc\/mdv482","journal-title":"Ann Oncol"},{"key":"3088_CR32","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s00520-017-3857-7","volume":"26","author":"K Jordan","year":"2018","unstructured":"Jordan K, Bl\u00e4ttermann L, Hinke A et al (2018) Is the addition of a neurokinin-1 receptor antagonist beneficial in moderately emetogenic chemotherapy?-a systematic review and meta-analysis. Support Care Cancer 26:21\u201332. https:\/\/doi.org\/10.1007\/s00520-017-3857-7","journal-title":"Support Care Cancer"},{"key":"3088_CR33","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.2217\/fon-2017-0712","volume":"14","author":"Y Zhang","year":"2018","unstructured":"Zhang Y, Hou X, Zhang R et al (2018) Optimal prophylaxis of chemotherapy-induced nausea and vomiting for moderately emetogenic chemotherapy: a meta-analysis. Future Oncol 14:1933\u20131941. https:\/\/doi.org\/10.2217\/fon-2017-0712","journal-title":"Future Oncol"},{"key":"3088_CR34","doi-asserted-by":"publisher","first-page":"90","DOI":"10.4143\/crt.2017.577","volume":"51","author":"SY Jeon","year":"2019","unstructured":"Jeon SY, Han HS, Bae WK et al (2019) A randomized, double-blind, placebo-controlled study of the safety and efficacy of olanzapine for the prevention of chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy: results of the Korean south west oncology group (KSWOG) study. Cancer Res Treat 51:90\u201397. https:\/\/doi.org\/10.4143\/crt.2017.577","journal-title":"Cancer Res Treat"},{"key":"3088_CR35","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/1756-9966-28-131","volume":"28","author":"L Tan","year":"2009","unstructured":"Tan L, Liu J, Liu X et al (2009) Clinical research of olanzapine for prevention of chemotherapy-induced nausea and vomiting. J Exp Clin Cancer Res 28:131. https:\/\/doi.org\/10.1186\/1756-9966-28-131","journal-title":"J Exp Clin Cancer Res"},{"key":"3088_CR36","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1007\/s00520-007-0248-5","volume":"15","author":"RM Navari","year":"2007","unstructured":"Navari RM, Einhorn LH, Loehrer PJ Sr et al (2007) A phase II trial of olanzapine, dexamethasone, and palonosetron for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier Oncology Group study. Support Care Cancer 15:1285. https:\/\/doi.org\/10.1007\/s00520-007-0248-5","journal-title":"Support Care Cancer"},{"key":"3088_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/JGO.17.00216","volume":"4","author":"AAM Osman","year":"2018","unstructured":"Osman AAM, Elhassan MMA, AbdElrahim BHA et al (2018) Olanzapine for the prevention of chemotherapy-induced nausea and vomiting: A comparative study from Sudan. J Glob Oncol 4:1\u20139. https:\/\/doi.org\/10.1200\/JGO.17.00216","journal-title":"J Glob Oncol"},{"key":"3088_CR38","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1007\/s00520-014-2175-6","volume":"22","author":"M Popovic","year":"2014","unstructured":"Popovic M, Warr DG, Deangelis C et al (2014) Efficacy and safety of palonosetron for the prophylaxis of chemotherapy-induced nausea and vomiting (CINV): a systematic review and meta-analysis of randomized controlled trials. Support Care Cancer 22:1685\u20131697. https:\/\/doi.org\/10.1007\/s00520-014-2175-6","journal-title":"Support Care Cancer"},{"key":"3088_CR39","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.3111\/13696998.2013.832257","volume":"16","author":"PJE Miller","year":"2013","unstructured":"Miller PJE, Balu S, Buchner D et al (2013) Willingness to pay to prevent chemotherapy induced nausea and vomiting among patients with breast, lung, or colorectal cancer. J Med Econ 16:1179\u20131189. https:\/\/doi.org\/10.3111\/13696998.2013.832257","journal-title":"J Med Econ"},{"key":"3088_CR40","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1007\/s10147-015-0786-7","volume":"20","author":"K Tamura","year":"2015","unstructured":"Tamura K, Aiba K, Saeki T et al (2015) Testing the effectiveness of antiemetic guidelines: results of a prospective registry by the CINV Study Group of Japan. Int J Clin Oncol 20:855\u2013865. https:\/\/doi.org\/10.1007\/s10147-015-0786-7","journal-title":"Int J Clin Oncol"},{"key":"3088_CR41","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1056\/NEJMp0911494","volume":"362","author":"E Basch","year":"2010","unstructured":"Basch E (2010) The missing voice of patients in drug-safety reporting. N Engl J Med 362:865\u2013869. https:\/\/doi.org\/10.1056\/NEJMp0911494","journal-title":"N Engl J Med"},{"key":"3088_CR42","doi-asserted-by":"publisher","first-page":"3475","DOI":"10.1007\/s00520-017-3770-0","volume":"25","author":"C Riese","year":"2017","unstructured":"Riese C, Wei\u00df B, Borges U Jr et al (2017) Effectiveness of a standardized patient education program on therapy-related side effects and unplanned therapy interruptions in oral cancer therapy: a cluster-randomized controlled trial. Support Care Cancer 25:3475\u20133483. https:\/\/doi.org\/10.1007\/s00520-017-3770-0","journal-title":"Support Care Cancer"},{"key":"3088_CR43","doi-asserted-by":"publisher","first-page":"2669","DOI":"10.1007\/s00520-012-1385-z","volume":"20","author":"A Liekweg","year":"2012","unstructured":"Liekweg A, Westfeld M, Braun M et al (2012) Pharmaceutical care for patients with breast and ovarian cancer. Support Care Cancer 20:2669\u20132677. https:\/\/doi.org\/10.1007\/s00520-012-1385-z","journal-title":"Support Care Cancer"},{"key":"3088_CR44","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1111\/j.1365-2753.2011.01665.x","volume":"18","author":"H Iihara","year":"2012","unstructured":"Iihara H, Ishihara M, Matsuura K et al (2012) Pharmacists contribute to the improved efficiency of medical practices in the outpatient cancer chemotherapy clinic. J Eval Clin Pract 18:753\u2013760. https:\/\/doi.org\/10.1111\/j.1365-2753.2011.01665.x","journal-title":"J Eval Clin Pract"},{"key":"3088_CR45","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/s10916-020-01663-x","volume":"44","author":"TM Rico","year":"2020","unstructured":"Rico TM, Dos Santos Machado K, Fernandes VP et al (2020) Use of text messaging (SMS) for the management of side effects in cancer patients undergoing chemotherapy treatment: a randomized controlled trial. J Med Syst 44:193. https:\/\/doi.org\/10.1007\/s10916-020-01663-x","journal-title":"J Med Syst"},{"key":"3088_CR46","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1002\/cam4.1002","volume":"6","author":"KH Mooney","year":"2017","unstructured":"Mooney KH, Beck SL, Wong B et al (2017) Automated home monitoring and management of patient-reported symptoms during chemotherapy: results of the symptom care at home RCT. Cancer Med 6:537\u2013546. https:\/\/doi.org\/10.1002\/cam4.1002","journal-title":"Cancer Med"},{"key":"3088_CR47","doi-asserted-by":"publisher","first-page":"1983","DOI":"10.1007\/s00520-010-1042-3","volume":"19","author":"M Majem","year":"2011","unstructured":"Majem M, Moreno ME, Calvo N et al (2011) Perception of healthcare providers versus patient reported incidence of chemotherapy-induced nausea and vomiting after the addition of NK-1 receptor antagonists. Support Care Cancer 19:1983\u20131990. https:\/\/doi.org\/10.1007\/s00520-010-1042-3","journal-title":"Support Care Cancer"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-026-03088-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-026-03088-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-026-03088-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T13:08:48Z","timestamp":1787663328000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-026-03088-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,1]]},"references-count":47,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["3088"],"URL":"https:\/\/doi.org\/10.1007\/s10147-026-03088-x","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,1]]},"assertion":[{"value":"26 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in this study were carried out in accordance with the ethical standards of the institutional and\/or national research committee and the 1964 Helsinki Declaration and its later amendments, or comparable ethical standards. This study was approved by the Institutional Review Board of the Hokkaido University Hospital (approval number: 025-0228). The requirement for formal consent for this study was waived by the Institutional Review Board of the Hokkaido University Hospital.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}}]}}